Bio-Rad Q4 sales up 3.9% to $693.2 million; GAAP operating loss of $118.9 million
Bio-Rad reported fourth-quarter 2025 revenue of $693.2 million, up 3.9% from a year earlier, but its GAAP operating result was a loss of $118.9 million after a $172.8 million impairment. Non-GAAP diluted earnings per share fell to $2.51 from $2.90, while GAAP net income of $720.0 million was driven mainly by a gain on its Sartorius AG investment. The company also gave a 2026 outlook of non-GAAP currency neutral revenue growth of about 0.5% to 1.5% and a non-GAAP operating margin of about 12.0% to 12.5%.
Key points
- Q4 2025 revenue was $693.2 million, up 3.9% from $667.5 million; currency neutral growth was 1.7%
- GAAP loss from operations was $118.9 million, including a $172.8 million impairment; non-GAAP operating income was $83.0 million, down from $92.1 million
- GAAP net income was $720.0 million, or $26.65 per diluted share, mainly from a change in the fair market value of the Sartorius AG investment; non-GAAP diluted EPS was $2.51 versus $2.90
- 2026 outlook: non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and non-GAAP operating margin of approximately 12.0% to 12.5%
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.